Modality
ASO
MOA
SOS1i
Target
KRASG12C
Pathway
Checkpoint
FSGSSMACholangiocarcinoma
Development Pipeline
Preclinical
Jun 2024
→ Mar 2029
PreclinicalCurrent
NCT03824765
1,029 pts·FSGS
2024-06→TBD·Active
NCT04331864
1,527 pts·Cholangiocarcinoma
2024-11→2029-03·Terminated
2,556 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-03-092.9y awayInterim· Cholangiocarcinoma
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Preclinical
Active
Preclinical
Termina…
Catalysts
Interim
2029-03-09 · 2.9y away
Cholangiocarcinoma
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03824765 | Preclinical | FSGS | Active | 1029 | DOR |
| NCT04331864 | Preclinical | Cholangiocarcinoma | Terminated | 1527 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 |